PEANUT ALLERGY
Clinical trials for PEANUT ALLERGY explained in plain language.
Never miss a new study
Get alerted when new PEANUT ALLERGY trials appear
Sign up with your email to follow new studies for PEANUT ALLERGY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a shot end peanut allergies? early safety trial begins
Disease control OngoingThis early-stage study tests a new treatment called VLP Peanut to see if it is safe and tolerable for people with peanut allergies. It includes both healthy volunteers and those allergic to peanuts. The goal is to check for side effects and get an early look at whether the treatm…
Matched conditions: PEANUT ALLERGY
Phase: PHASE1 • Sponsor: Allergy Therapeutics • Aim: Disease control
Last updated May 15, 2026 07:21 UTC
-
Peanut allergy treatment shows promise in large study
Disease control OngoingThis study looks at how well oral immunotherapy (eating small, increasing amounts of peanut protein) works for people with peanut allergy. About 500 participants aged 6 months to 65 years will be followed for two years to see if they can tolerate a daily maintenance dose of 300 m…
Matched conditions: PEANUT ALLERGY
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 15, 2026 07:18 UTC
-
Peanut allergy pill shows promise in early trial
Disease control OngoingThis study tests a daily tablet placed under the tongue to help children, teens, and adults with peanut allergy tolerate small amounts of peanut protein. The goal is to see if the tablet is safe and can raise the amount of peanut a person can eat without having an allergic reacti…
Matched conditions: PEANUT ALLERGY
Phase: PHASE1, PHASE2 • Sponsor: ALK-Abelló A/S • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New shot could help kids tolerate peanuts, study shows
Disease control OngoingThis study tests a new immunotherapy called PVX108 for children and teens with peanut allergy. The goal is to see if it safely helps them tolerate more peanut protein without a severe reaction. About 90 participants aged 4 to 17 will receive either PVX108 or a placebo over severa…
Matched conditions: PEANUT ALLERGY
Phase: PHASE2 • Sponsor: Aravax Pty Ltd • Aim: Disease control
Last updated May 11, 2026 20:38 UTC